BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patientâ€™s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
12/06/26	3.800 $	-1.30%	10,732
11/06/26	3.850 $	-4.47%	24,114
10/06/26	4.030 $	-4.73%	3,656
09/06/26	4.230 $	-1.17%	10,964
08/06/26	4.280 $	-0.70%	1,446

Delayed Quote Toronto S.E.

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Toronto S.E. Other stock markets 22:59:35 12/06/2026 +03			5-day change	1st Jan Change
3.800 ^CAD	-1.30%		-11.83%	-61.22%

06-09	BriaCell Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2026	CI
06-02	BriaCell Therapeutics Rises After Hours as It Closes a $4.7-Million Share Offering	MT

Market Cap	23.68M 20.45M 18.85M 17.64M 33.06M 2.25B 33.57M 223M 86.76M 1.1B 88.86M 86.97M 3.79B	P/E Ratio 2024	-2.56x	P/E Ratio 2025	-0.12x
Enterprise Value	5.81M 5.02M 4.63M 4.33M 8.11M 552M 8.24M 54.62M 21.3M 269M 21.81M 21.35M 931M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	99.49%	Yield 2024 *	-	Yield 2025	-

06-09	BriaCell Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2026	CI
06-02	BriaCell Therapeutics Rises After Hours as It Closes a $4.7-Million Share Offering	MT
06-02	BriaCell Therapeutics Closes $4.7 Million Share Offering	MT
06-01	BriaCell Presenting Final Phase 2, Ongoing Phase 3 Data at ASCO Meeting	MT
06-01	BriaCell Down 9.3% as Prices Offering to Raise US$4.7 Million	MT
06-01	BriaCell Therapeutics Prices $4.7 Million Share Offering	MT
06-01	Briacell Therapeutics prices 1.45 million common shares at $3.25 per share	RE
05-26	Briacell Therapeutics Corp. Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study of Bria-Imt Plus Immune Checkpoint Inhibitor in Metastatic Breast Cancer	CI
05-26	BriaCell Receives DSMB Nod to Continue With Phase 3 Metastatic Breast Cancer Study	MT
05-26	BriaCell Says Received Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer	MT
05-26	Briacell receives positive recommendation from data safety monitoring board (DSMB) for phase 3 study in metastatic breast cancer	RE
05-22	BriaCell Says Presenting Posters, Publication-only Abstracts at ASCO 2026	MT
05-15	BriaCell Therapeutics Developing Ovarian Cancer Immunotherapy Candidate	MT

22/10/25	Briacell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer	CI
22/10/25	Briacell receives positive recommendation from data safety monitoring board (DSMB) for phase 3 study in metastatic breast cancer	RE
15/10/25	BriaCell Therapeutics Corp. Auditor Raises 'Going Concern' Doubt	CI
25/02/25	Wedbush Initiates BriaCell Therapeutics at Outperform With $15 Price Target	MT
29/10/24	BriaCell Therapeutics Corp. Auditor Raises 'Going Concern' Doubt	CI

BriaCell Therapeutics Corp. Stock

Stocks

BCT

CA1079303071

Biotechnology & Medical Research

Valuation: BriaCell Therapeutics Corp.

Chart: BriaCell Therapeutics Corp.

Latest news : BriaCell Therapeutics Corp.

Analysts' recommendations: BriaCell Therapeutics Corp.

Press Releases: BriaCell Therapeutics Corp.

Quotes and Performance

Course Extremes

Managers and Directors: BriaCell Therapeutics Corp.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

06-02	BriaCell Therapeutics Announces Closing of Offering	AQ
06-01	BriaCell Presents Positive Clinical Data at ASCO 2026	AQ
06-01	BriaCell Therapeutics Announces Pricing of Offering	AQ
05-26	BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer	AQ
05-22	BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026	AQ

1 day	-1.30%
1 week	-11.83%
Current month	-24.45%
1 month	-31.90%
3 months	-33.68%
6 months	-71.73%
Current year	-61.22%

1 week	3.68	4.38
1 month	3.68	5.91
Current year	3.68	16.5
1 year	3.68	44.1
3 years	3.68	1,543.5
5 years	3.68	2,362.5
10 years	3.68	11,250.11

Manager	Title	Age	Since
William Williams CEO	Chief Executive Officer	70	01/11/2016
Gadi Levin DFI	Director of Finance/CFO	54	01/02/2016
Guiseppe Del Priore CTO	Chief Tech/Sci/R&D Officer	65	16/02/2022

Director	Title	Age	Since
William Williams BRD	Director/Board Member	70	01/11/2016
Jamieson Bondarenko CHM	Chairman	41	24/04/2019
Rebecca Taub BRD	Director/Board Member	73	07/03/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
02-19	Guiseppe Del Priore	Option	Chief Technology Officer	37,700	0.6069%
02-19	Miguel Lopez-Lago	Option	Chief Technology Officer	30,000	0.4830%
02-19	Miguel Lopez-Lago	Option	Chief Technology Officer	30,000	0.4830%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BRIACELL THERAPEUTICS CORP.	-1.30%	-11.83%	-92.20%	-99.68%	23.92M
ARGENX SE	+1.03%	+2.30%	+54.92%	+111.78%	55.58B
WUXI APPTEC CO., LTD.	+2.72%	+3.26%	+47.26%	+47.26%	43.47B
BIONTECH SE	+1.12%	+2.79%	-13.71%	-17.53%	22.64B
INSMED INCORPORATED	+1.17%	+3.85%	+1.00%	+401.79%	20.96B
WUXI BIOLOGICS (CAYMAN) INC.	+3.81%	-5.07%	+12.00%	-29.52%	15.79B
GENMAB A/S	+0.15%	+2.24%	+9.10%	-40.04%	15.3B
EXELIXIS, INC.	-0.69%	+0.82%	+27.17%	+178.31%	13.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+5.27%	+5.54%	+14.25%	-	11.74B
PHARMAESSENTIA CORPORATION	+1.61%	+1.28%	+92.88%	+215.31%	10.96B
Average	+1.49%	-0.55%	+15.27%	+85.30%	20.99B
Weighted average by Cap.	+1.71%	+1.60%	+31.89%	+100.77%

	2024	2025
Net sales	-	-
Net income	-4.79M -4.14M -3.81M -3.57M -6.69M -455M -6.79M -45.03M -17.56M -222M -17.98M -17.6M -768M	-26.31M -22.73M -20.94M -19.6M -36.74M -2.5B -37.3M -247M -96.41M -1.22B -98.75M -96.65M -4.21B
Net Debt	-862K -745K -686K -642K -1.2M -81.94M -1.22M -8.1M -3.16M -39.88M -3.24M -3.17M -138M	-17.87M -15.43M -14.22M -13.31M -24.94M -1.7B -25.33M -168M -65.46M -827M -67.05M -65.62M -2.86B